Compare BORR & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | CTY |
|---|---|---|
| Founded | 2016 | 2023 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 995.8M | 1.0B |
| IPO Year | 2017 | 2026 |
| Metric | BORR | CTY |
|---|---|---|
| Price | $3.44 | $17.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $4.93 | ★ $37.33 |
| AVG Volume (30 Days) | ★ 8.5M | 250.4K |
| Earning Date | 11-18-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $62.96 |
| Revenue Next Year | $17.14 | $7.47 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.89 | $15.81 |
| 52 Week High | $6.66 | $22.65 |
| Indicator | BORR | CTY |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 41.04 |
| Support Level | $3.10 | $16.12 |
| Resistance Level | $4.64 | $21.98 |
| Average True Range (ATR) | 0.20 | 2.35 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 31.90 | 25.44 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.